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Cardiac sequelae of past SARS-CoV-2 infection are still poorly documented. We conducted a 
cross-sectional study in health-care workers to report evidence of pericarditis and myocarditis 
after SARS-CoV-2 infection. 
Methods 
We studied 139 health-care workers with confirmed past SARS-CoV-2 infection (103 
diagnosed by RT-PCR and 36 by serology). Participants underwent clinical assessment, 
electrocardiography, laboratory tests including immune cell profiling and cardiac magnetic 
resonance (CMR). Pericarditis was diagnosed when classical criteria were present, and the 
diagnosis of myocarditis was based on the updated CMR Lake-Louise-Criteria. 
Results 
Median age was 52 years (IQR 41–57), 100 (72%) were women, and 23 (16%) were previously 
hospitalized for Covid-19 pneumonia. At examination (10.4 [9.3–11.0] weeks after infection-
like symptoms), all participants presented hemodynamic stability. Chest pain, dyspnoea or 
palpitations were observed in 58 (42%) participants; electrocardiographic abnormalities in 69 
(50%); NT-pro-BNP was elevated in 11 (8%); troponin in 1 (1%); and CMR abnormalities in 
104 (75%). Isolated pericarditis was diagnosed in 4 (3%) participants, myopericarditis in 15 
(11%) and isolated myocarditis in 36 (26%). Participants diagnosed by RT-PCR were more 
likely to still present symptoms than participants diagnosed by serology (73 [71%] vs 18 [50%]; 
p=0.027); nonetheless, the prevalence of pericarditis or myocarditis was high in both groups (44 
[43%] vs 11 [31%]; p=0.238). Most participants (101 [73%]) showed altered immune cell 
counts in blood, particularly decreased eosinophil (37 [27%]; p<0.001) and increased CD4-CD8-
/loTαβ-cell numbers (24 [17%]; p<0.001). Pericarditis was associated with elevated CD4-CD8-
/loTαβ-cell numbers (p=0.011), while participants diagnosed with myopericarditis or 
myocarditis had lower (p<0.05) plasmacytoid dendritic cell, NK-cell and plasma cell counts and 
lower anti-SARS-CoV-2-IgG antibody levels (p=0.027). 
Conclusions 
Pericarditis and myocarditis with clinical stability are frequent long after SARS-CoV-2 
infection, even in presently asymptomatic subjects. These observations will probably apply to 
the general population infected and may indicate that cardiac sequelae might occur late in 
association with an altered (delayed) innate and adaptative immune response. 
 
The trial is registered with ClinicalTrials.gov, number NCT04413071 
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Research in context 
Evidence before this study 
Very little evidence exists describing long cardiac sequelae after SARS-CoV-2 
infection. Although pericarditis and myocarditis are the two most frequent cardiac 
manifestations observed after a viral infection, as of May 13, 2020, the peer-reviewed literature 
was limited to isolated case reports of myocarditis and pericarditis during the COVID-19 
hospitalization phase and to a retrospective observation in 26 recovered patients with COVID-
19 pneumonia presenting cardiac complaints during hospitalization, revealing the presence of 
myocardial oedema in 14 (54%) patients and late gadolinium enhancement in 8 (31%) patients. 
These small size case series, limited to hospitalized RT-PCR patients with COVID-19 
pneumonia, are insufficient to generalize conclusions about the true prevalence of pericardial 
and myocardial long involvement after SARS-CoV-2 infection. In addition, no study has 
investigated the immunological consequences of SARS-CoV-2 infection in the settings of 
pericarditis and myocarditis. 
Added value of this study 
To our knowledge, this is the largest cohort of subjects (N=139) —even for other 
common viruses— with clinical, electrocardiographic, laboratory and CMR imaging 
evaluations, to assess pericardial and myocardial involvements after SARS-CoV-2 infection. 
The strength of this study is the addition of non-hospitalized participants and also the inclusion 
of participants diagnosed of past SARS-CoV-2 infection through serology. Contrary to previous 
studies, women are well represented. We found a prevalence of pericarditis or myocarditis up to 
40% cases; pericarditis coexisted with some degree of concurrent myocardial inflammation in 
11% cases. Study participants who were previously hospitalized for COVID-19 pneumonia and 
patients who received antiviral (hydroxychloroquine, lopinavir-ritonavir) or anti-inflammatory 
(high-dose glucocorticoids and anti-interleukin treatments) treatments, and who were on chronic 
drug treatment with statins, were less likely to develop pericarditis or myocarditis. The clinical 
assessment of the participants showed clinical stability without any patient presenting severe 
pericardial effusion, heart failure or left ventricular dysfunction. We provide new data on 
seropositive subjects; although RT-PCR participants were more likely to still present symptoms 
than participants diagnosed by serology, the prevalence of pericarditis, myocarditis or 
myocarditis, almost three months after the initial viral prodrome, was high in both groups. In-
depth investigation of the distribution of multiple major and minor populations of immune cells 
in blood showed high frequency of altered immune profiles after SARS-CoV-2 infection. The 
altered immune cell profiles identified partially mimic abnormalities previously reported during 
active infection together with others described here for the first time, with unique patterns 
associated with pericardial and/or myocardial injury. Nonetheless, we also described altered 
immune profiles in participants without pericardial and myocardial manifestations. Whether 
these later alterations are due to persistence of tissue damage in other organs affected by SARS-
CoV-2, such as the lung, or they reflect normal post-infection immune recovery mechanisms, 
remains to be investigated. 
Implications of all the available evidence 
At present, there is much interest in the long-term sequelae of COVID-19. It is 
intriguing that pericarditis and myocarditis were observed so long after SARS-CoV-2 infection 
and also in some presently asymptomatic subjects, in association with notably altered immune 
cell profiles in blood. These observations will probably apply to the general population infected 
and may indicate that cardiac sequelae might occur late, paving the way for a better 
understanding the immune mechanisms involved. Thus, our study may have health-care 
consequences given the widespread diagnosis of SARS-CoV-2 infection in population-based 
seroprevalence studies. 
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Introduction 
Pericarditis and myocarditis are the two most frequent cardiac manifestations observed 
after a viral infection1,2. Symptoms tend to be non-specific and most cases resolve without long-
term sequelae.  That is why the true incidence of pericarditis and myocarditis after common 
viral infections —influenza, parvovirus, coxsackievirus, echovirus, adenovirus, echovirus, 
herpesvirus or cytomegalovirus— is still unknown in the general population.  
The novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is currently 
causing a sustained covid-19 pandemic, with the risk of causing long-term cardiac sequelae in 
the infected population3. The fear of SARS-CoV-2 causing greater myocardial damage than 
other conventional viruses is based on its mechanism of infecting human cells by binding to the 
transmembrane angiotensin-converting-enzyme-24, which is mainly expressed by cells in alveoli 
and myocardial tissue5; the rise in troponin levels observed in covid-19 patients hospitalized 
with pneumonia and its association with increased mortality6,7; and the probably reduced innate 
antiviral defences against a novel virus8.  
Pericarditis and myocarditis after conventional viral infections both stem from an 
inadequate or excessive immune response driven by T and B cell-mediated mechanisms1,2,9. In 
case of an inadequate response, continued viral replication in the peri-myocardium protracts 
inflammation by attracting killer T cells and the concomitant production of chemokines and 
cytokines. In contrast, molecular mimicry can result in the production of autoantibodies against 
cardiac proteins, leading to a cardio-specific autoimmune response that causes sustained 
inflammation, effusion or cardiac remodeling. However, the specific immune profiles that occur 
after SARS-CoV-2 infection, particularly in patients presenting with cardiac sequelae remain 
unknown10.  
The present study was designed to search for evidence of pericardial and myocardial 
involvement after past SARS-CoV-2 infection comprehensively studied by clinical assessment, 
laboratory tests, electrocardiography and cardiac magnetic resonance (CMR) imaging. 
Additionally, participants underwent an in-depth characterization of the immune cell 
compartments in blood and the virus-specific humoral immune response in this clinical 
scenario. As health-care workers have been the group most affected by SARS-CoV-2 in Spain, 
but have also been subject to more testing than the rest of the population, we decided to conduct 
the study in this singular cohort. 
Methods 
Study design and health-care workers participants 
This cross-sectional, observational, cohort study consecutively recruited 142 health-care 
workers with laboratory confirmed SARS-CoV-2 infection in Salamanca, Spain, and who 
volunteered for the study. Among them, 106 health-care workers tested positive for SARS-
CoV-2 by RT-PCR between March 13 and April 25; and 36 health-care workers were diagnosed 
after testing positive for anti-SARS-CoV-2-IgG antibodies between April 10 and May 22. The 
purpose of this second group was to also provide data from subjects with past SARS-CoV-2 
infection in whom symptoms of viral infection are more likely to be mild and because 
population-based SARS-CoV-2 seroprevalence studies are becoming more established11,12. 
Study enrolment began on May 25 and finished on June 12, 2020. 
Institutional approval (2020/05/490) for the study was provided by the University 
Hospital of Salamanca Ethics Committee, and all participants provided written informed 
consent. The study is registered with ClinicalTrials.gov NCT04413071. The responsibility for 
the study design, data collection and data interpretation lay solely with the study investigators. 
An internal adjudication monitoring board reviewed all cardiac study findings and adjudicated 
study outcomes. The authors had full access to all the data and elaborated all materials to submit 
for publication. 
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Investigation process and procedures 
All participants underwent clinical evaluation, electrocardiography, laboratory tests and 
CMR imaging at the same visit. After obtaining written informed consent, trained interviewers 
used a structure questionnaire to collect baseline data in face-to-face interviews. A cardiologist 
took a complete medical history, performed a physical examination and reviewed the 
completeness of the questionnaire in a separate room, where an electrocardiogram was 
performed, and blood samples were drawn immediately before the CMR. Electrocardiograms 
were interpreted in consensus by two experienced readers, who were blinded to participant 
identification, clinical history, symptoms, physical examination and other findings.  
CMR was performed using a clinical 1.5 whole-body magnetic resonance scanner in the 
cardiac imaging laboratory of the University Hospital of Salamanca13. Functional imaging was 
performed using standard segmented cine steady-state free-precession sequence with breath 
holding. Myocardial oedema was identified using a T2-weighted short-tau triple inversion-
recovery (T2W-STIR) sequence. T2-relaxation time properties were obtained using a T2-
gradient spin-echo (T2-GraSE) mapping sequence. Assessment of T1-relaxation times and free 
water content within the myocardium (extracellular volume) were identified using a modified 
look-locker inversion recovery-MOLLI-with-5(3)3 acquisition scheme before and 15 minutes 
after intravenous administration of 0.15 mmol per kg body weight of gadobutrol contrast media 
agent. Late gadolinium enhancement was identified on a series of T1-weighted inversion 
recovery turbo field echo sequence, acquired 10 to 15 minutes after the contrast administration. 
CMR images were globally and regionally analysed using dedicated software, in consensus by 
two experienced readers, who were blinded in a similar manner to the electrocardiogram 
protocol, following conventional CMR methods (supplementary methods). T2 and T1-based 
markers of myocardial inflammation were analysed in each of the 16 segments of the 17-
segment model of the American Heart Association (the true apex was excluded)14, where only 
positive segment concordances from the different T2 and T1-based markers were considered. 
Because myocarditis was diagnosed according to these T2 and T1-based CMR markers and an 
adequate selection of normal reference values is fundamental, we used as controls CMR 
imaging from 20-sex-and-aged matched individuals without cardiac disease from the general 
population of the province of Salamanca, Spain (NCT03429452)15.  
Immunophenotypic analysis of (>250) immune cell populations was performed in 
peripheral blood samples collected in K3-EDTA (10mL/sample) and stained with the EuroFlow 
lymphocyte screening tube (LST) and the TCD4, NK/TCD8, BIgH and MoDC immune 
monitoring (IMM) tubes by flow cytometry (FACSCANTO II and LSR-Fortessa, respectively; 
Becton/Dickinson Biosciences, San José, California) using a dual-platform assay previously 
described in detail16,17. All protocols are available at www.euroflow.org. Reference values were 
defined based on a cohort of 463 age-matched adults (median age 52 years [IQR 47-61]) from 
the general population of the province of Salamanca, Spain. Anti-SARS-CoV-2-IgM 
(AnshLabs, Webster, Texas), IgG and IgA (Mikrogen Diagnostik, Neuried, Germany) antibody 
levels were measured in parallel in plasma from the same blood samples using commercially 
available IVD approved (semi-quantitative) ELISA kits, strictly as instructed by the 
manufacturers.  
Study outcomes and definitions 
Study outcome measures were the prevalence of pericarditis and of myocarditis. 
Pericarditis was diagnosed if at least two of the following criteria were present, following 
current guidelines1: pericarditic chest pain, pericardial rub on auscultation, widespread ST-
elevation or PR depression on ECG, and evidence of pericardial effusion at CMR. Elevation of 
inflammation markers, C-reactive protein, and evidence of pericardial inflammation at CMR 
were used as additional supporting findings. The diagnosis of myocarditis was based on the 
updated CMR Lake-Louis-Criteria (LLC)18, which consider as main LLC criteria for 
myocarditis positive oedema-sensitive T2-based markers (T2-weighted images or T2-mapping) 
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or positive T1-based tissue characterization markers (abnormal T1-relaxation time or 
extracellular volume or late gadolinium enhancement), and as supportive LLC criteria either 
pericardial effusion, or evidence of pericardial inflammation at CMR, or systolic left ventricle 
wall motion abnormalities. Considering that participants were being examined beyond the acute 
phase of SARS-CoV-2 infection; myocarditis was defined as having a combination of at least 
two T2 or T1-based LLC main criteria or having a combination of only one T2 or T1-based 
LLC main criterion with one additional LLC supportive criterion.  
As we were aware that pericarditis and myocarditis occur together in clinical practice, 
we hence defined as myopericarditis those cases of pericarditis with associated myocarditis on 
CMR but without left ventricle wall motion abnormalities, and as perimyocarditis those cases 
where left ventricle wall motion abnormalities were present19.  
Statistical Analysis 
 Descriptive statistics were used to summarized the data; results are presented as the 
proportion (%) of valid cases for categorical variables and as the median (IQR) for continuous 
variables. As the participants in our study were not randomly selected, all statistics are deemed 
descriptive only; nonetheless, differences between groups are also provided and were analysed 
by Fisher´s exact test for categorical variables and by nonparametric Mann-Whitney or Kruskal-
Wallis for continuous data. We compared characteristics of participants and examinations, all 
Tables, according to the final clinical diagnosis (non-pericardial and myocardial manifestations 
vs pericarditis vs myopericarditis vs myocarditis). For 2-dimensional visualization of flow 
cytometry data, multivariate canonical analysis with multidimensional reduction of data via 
linear discriminant analysis, and the t-distributed stochastic neighbour embedding (t-SNE) 
machine-learning algorithm visualization tools, were used (Infinicyt software, Cytognos, 
Salamanca, Spain)20.  
Results 
Study Population 
 Figure 1 depicts the flowchart for participant selection from the health-care workers. 
From the 142 recruited health-care workers who signed informed consent, one participant did 
not complete the CMR for claustrophobia. Two additional participants were excluded because 
history of severe hypertrophic myocardiopathy in one case, and inherited immune deficiency in 
the other. Thus, a total of 139 participants completed clinical assessment, electrocardiography, 
laboratory tests and CMR. Of these, 103 (74%) had been diagnosed by RT-PCR and 36 (26%) 
by serology. 
 All participant characteristics are shown in table 1. Median age was 52 years (41–57) 
and most were female, 100 (72%). By professional categories, 49 (35%) were nurses, 35 (25%) 
medical doctors, and the remaining 55 (40%) included different profiles such as auxiliary nurses 
and other hospital staff. A total of 67 (48%) health-care workers were infected while directly 
attending covid-19 hospitalization wards. 
Among the overall study population, 106 (76%) had at least one comorbidity and 8 
(6%) health-care workers presented a history of cardiovascular disease; one with chronic 
ischemia with stent revascularization, three with paroxysmal atrial fibrillation, two with 
intranodal supraventricular tachycardias treated with ablation, and two with an episode of acute 
pericarditis several years before. 
Most (137 [98%]) health-care workers experienced a viral prodrome at SARS-CoV-2 
infection. Fatigue was reported by 117 (84%) participants, fever by 94 (68%), cough by 91 
(65%), headache by 90 (65%) and myalgia by 83 (60%). Cardiac symptoms with shortness of 
breath, chest pain, palpitations or dizziness were reported by 86 (62%) participants. 
A total of 27 (19%) health-care workers were previously diagnosed with covid-19 
pneumonia and 23 (16%) required hospitalization. Overall, the drug therapy aimed at 
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ameliorating the disease was heterogeneous: hydroxychloroquine was given in 33 (24%) cases, 
lopinavir-ritonavir in 17 (12%), oral glucocorticoids in 9 (6%), high-dose intravenous bolus of 
methylprednisolone in 15 (11%), and interleukin inhibitors in 18 (13%). 
Symptoms, electrocardiographic, biochemical, and cardiac magnetic resonance profiling 
The study examinations (table 2) were performed 10·4 (9·3–11·0) weeks after 
symptoms of infection began; 9·4 (8·1–10·0) weeks after the positive test for RT-PCR 
participants and 4·4 (3·6–5·0) weeks for participants diagnosed through antibodies testing. 
All participants presented vital and exploratory signs of hemodynamic stability at 
examination. 91 (65%) health-care workers still presented symptoms with fatigue being 
reported in 37 (27%) cases, and those cardiac-related, such as shortness of breath in 36 (26%) 
cases, chest pain in 27(19%), or palpitations in 20 (14%).  
Of the 139 electrocardiograms, electrocardiographic abnormalities were reported in 69 
(50%) cases. Minnesota codes abnormalities were observed in 49 (35%) participants 
(supplementary table A), QT interval prolongation was observed in 5 (4%), and early 
repolarization in 8 (6%). A total of 33 (24%) electrocardiograms met criteria for pericarditis-like 
changes (supplementary figure A). 
Cardiac-specific and inflammatory biomarkers were within the normal range in most 
participants. Above the normal range, high-sensitivity troponin T concentration (≥14 pg. per 
millilitre) was increased in 1 (1%) participant, NT-pro-BNP (≥125 pg. per millilitre) in 11 (8%) 
and C-reactive protein (≥3 mg. per decilitre) in 10 (7%). 
CMR abnormalities were observed in 104 (75%) cases (complete data from CMR 
measures are in the supplementary tables B, C and D). 6 (4%) participants presented increased 
of myocardial T2-relaxation time, 6 (4%) oedema on T2-weighted images, 58 (42%) increased 
native myocardial T1-relaxation time, 52 (37%) increase of T1-extracellular volume, 10 (7%) 
T1-late gadolinium enhancement, 42 (30%) pericardial effusion, 1 (1%) a pericardial thickness 
of 3 mm and 7 (5%) systolic left ventricular wall motion abnormalities, global or regional 
(supplementary Figure B). 
Pericarditis and myocarditis prevalence 
A total of 55 (40%) participants fulfilled criteria for either pericarditis or myocarditis. 
Among them, 19 (14%) fulfilled criteria for pericarditis, 51 (37%) criteria for myocarditis, and 
15 (11%) fulfilled criteria for both pericarditis and myocarditis.  
Of the 19 participants fulfilling criteria for pericarditis, 15 (79%) presented two 
classical criteria and 4 (21%) three criteria. Of the 51 participants fulfilling criteria for 
myocarditis, 22 (43%) presented a combination of at least two T2 or T1-based LLC main 
criteria and 29 (57%) presented a combination of only one T2 or T1-based LLC main criterion 
with at least one additional LLC supportive criterion. Additional descriptions of criteria 
combinations are provided in figure 2. 
Clinical isolated pericarditis was then diagnosed in 4 (3%) cases, myopericarditis in 15 
(11%) and isolated myocarditis in 36 (26%). Baseline and examination characteristics for each 
diagnostic group are detailed in tables 1 and 2.  
A higher percentage of participants without pericardial or myocardial manifestations 
than participants with pericarditis, myopericarditis and myocarditis were on chronic drug 
therapy with statins (16 [19%] vs. 1 [2%]; p=0.003), were previously hospitalized for covid-19 
(19 [23%] vs. 4 [7%]; p=0.020), and received drug therapy aimed at ameliorating the disease: 
hydroxychloroquine (25 [30%] vs. 8 [14%]; p=0.043), lopinavir-ritonavir (14 [17%] vs. 3 [5%]; 
p=0·064) and interleukin inhibitors or high-doses of intravenous glucocorticoids (16 [19%] vs. 4 
[7%]; p=0.082). A higher percentage of participants with pericarditis, myopericarditis or 
myocarditis than participants without these manifestations presented cardiac symptoms at 
SARS-CoV-2 infection (40 [73%] vs. 46 [55%]; p=0.049) and at study examination (30 [54%] 
vs. 28 [33%]; p=0.015). 
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Participants with infection confirmed through anti-SARS-CoV-2-IgG detection 
Among the participants diagnosed with past infection through anti-SARS-CoV-2-IgG 
detection (data for this group, compared to RT-PCR participants, are shown in the appendix 
[supplementary table E), 28 (78%) were previously tested negative by RT-PCR after developing 
mild SARS-CoV-2 symptoms and 8 (22%) were never RT-PCR tested. A lower percentage of 
participants diagnosed through positive serology still presented symptoms at examination 
compared to RT-PCR participants (18 [50%] vs. 73 [71%]; p=0.027); nonetheless, the 
prevalence of pericarditis, myopericarditis or myocarditis was high in both groups (figure 3). 
Altered immune cell and humoral profiles in blood 
Most study participants (101 [73%]) displayed altered cell counts in blood for at least 
one major immune cell population as illustrated in figure 4A-B, and described in more detail in 
tables 3 and 4. Most frequent alterations consisted of eosinopenia (38 [27%] cases; p<0.001), 
and increased CD4-CD8-/lo Tαβ (cytotoxic) T-cell (24 [17%] cases; p<0.001); and, to a less 
extent also B-cell counts (16 [12%] cases; p<0.001). In addition, compared to age-matched 
healthy donors, participants had higher median counts in blood of basophils (38 vs. 47 cells/μL, 
respectively; p<0.013), total monocytes (317 vs 405 cells/μL; p<0.001) at the expense of 
classical (FcεRI-) monocytes (290 vs 386 cells/μL; p<0.001), total lymphocytes (1675 vs 2221 
cells/μL; p<0.001), including total T-lymphocytes (1246 vs 1652 cells/μL; p<0.001), TCD4 
(716 vs 1017 cells/μL; p<0.001), TCD8 (407 vs 507 cells/μL; p<0·001) and B lymphocytes (154 
vs 208 cells/μL; p<0.001); in contrast, participants showed decreased median numbers of 
circulating blood myeloid-derived suppressor cells (5 vs 2 cells/μL; p<0.001, immature CD16-
CD62L- neutrophils (5 vs 2 cells/μL; p<0.001),  intermediate monocytes (20 vs 14 cells/μL; 
p=0·001) and immunomodulatory FcεRI+CD62L+(46 vs 12; p=0.038) and FcεRI+CD62L- (7 vs 
2; p=0.001) monocytes,  plasmacytoid dendritic cells (8 vs 6 cells/μL; p=0.020), NK-cells (260 
vs 213 cells/μL; p=0.007) and circulating plasma cells (2 vs 0·8 cells/μL; p<0.001). 
Compared to healthy donors, participants with pericarditis showed the highest median 
counts in blood of CD4-CD8-/lo Tαβ (cytotoxic) T-cells (46 vs 137 cells/μL; p=0.011) and also 
displayed (similarly to cases with myopericarditis and those with myocarditis) decreased blood 
counts of FcεRI+CD62L+ immunomodulatory monocytes (46 vs 4, 2 and 11, respectively; 
p=0.020).  
Participants diagnosed with myopericarditis tended to share altered immune cell profiles 
with myocarditis, except for two cases with myopericarditis whose profiles more closely 
overlapped with those cases with pericarditis (figure 4B). Thus, compared to healthy donors, 
participants with myopericarditis and those with myocarditis specifically displayed more 
pronounced decreased counts in blood of  plasmacytoid dendritic cells (8 vs 6 and 5 cells/μL, 
respectively; p<0.001),  and NK-cells (260 vs 120 and 177 cells/μL; p<0.001), including the 
subset of  cytotoxic granzyme B (Gz)+CD57- of NK-cell, Tγδ and/or TCD8 cells (supplementary 
table F), and circulating plasma cells (2 vs 0·4 and 1 cells/μL; p<0.001) (supplementary table 
G). 
Finally, participants with myopericarditis and those with myocarditis presented lower 
amounts of anti-SARS-CoV-2-IgG antibodies (115 [42–156] and 114 [77–160] IU/mL, 
respectively) compared to participants without pericardial or myocardial manifestations (147 
[93–176] IU/mL; p=0.027) (figure 4C). Of note, among participants with myopericarditis, the 
above alterations were further associated with lower TCD4 Th17 lymphocytes (20 vs 33 
cells/μL; p=0.023) (supplementary table H).  
Discussion 
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This study examined the prevalence of pericarditis and of myocarditis in a cohort of 
SARS-CoV-2 positive health-care workers in Salamanca, Spain. In the largest cohort of subjects 
with CMR imaging assessment reported so far, we demonstrate that pericardial and myocardial 
involvement is highly prevalent after SARS-CoV-2 infection.  
We decided to carry out a study in health-care workers, as this sector has been 
disproportionally infected in Spain —approximately 20% of all COVID-19 cases21— which 
provided us with the opportunity to study the prevalence of pericarditis and myocarditis in 
SARS-CoV-2 infected cases that were confirmed by positive RT-PCR or positive serology. In 
addition, as the proportion of female health-care workers is high in Spain, our study does not 
underrepresent women who constituted more than two thirds of recruited participants. Unlike 
other observational studies suggesting that myocarditis may be slightly more prevalent in men 
than women22-24; men in our study presented lower prevalence of pericarditis or myocarditis 
than women (11 [28%] vs. 44 [44%]; p=0.122). This observation could be related, more than to 
gender, to the higher rate of previous hospitalization for COVID-19 pneumonia in men than 
women (13 [33%] vs. 10 [10%]; p=0.002) for our cohort. In general, previously hospitalized 
participants presented lower percentage of pericardial and myocardial injury compared to 
participants never hospitalized (4 [17%] vs. 51 [44%]; p=0.020). Having been hospitalized, 
participants received more treatment aimed at inhibiting viral replication (lopinavir-ritonavir or 
hydroxychloroquine) and reducing inflammation (high-dose glucocorticoids and interleukin 
inhibitors). The recent Recovery study (NCT04381936) has shown that low-dose 
dexamethasone reduces mortality in hospitalized COVID-19 patients. 
Case reports of myocarditis and pericarditis have been published during the COVID-19 
hospitalization phase25. A recent retrospective observation in 26 recovered patients with 
COVID-19 pneumonia presenting cardiac complaints during hospitalization, revealed the 
presence of myocardial oedema in 14 (54%) patients and late gadolinium enhancement in 8 
(31%) patients26. Our results are in agreement with these findings as 89 (64%) of our 
participants presented myocardial injury in T2 or in T1-based CMR. High rates of myocardial 
damage are also observed in influenza —where elevated cardiac enzymes, electrocardiographic, 
echocardiographic and histologic findings have been reported in approximately one third of 
cases27.  
Importantly, clinical assessment of our participants with pericarditis and myocarditis 
showed clinical stability without any participant presenting severe pericardial effusion, heart 
failure or left ventricular dysfunction (only four participants with myocarditis presented wall 
motion abnormalities). However, follow-up studies are necessary to determine the outcome of 
cardiac sequelae observed even in asymptomatic and pauci-symptomatic subjects after SARS-
CoV-2 infection28. Thus, the participants diagnosed of past infection through serology who were 
more likely to be asymptomatic or mildly symptomatic, and who might better represent the 
cases detected in population-wide seroprevalence studies11,12, presented a similar prevalence of 
pericardial and myocardial manifestations to RT-PCR positive participants (11 [31%] vs 44 
[43%]; p=0.238).  
At present, there is much interest in the long-term sequelae of COVID-19. It is 
intriguing that pericarditis, myopericarditis or myocarditis were observed that long after SARS-
CoV-2 infection (over 10 weeks after initial viral prodrome at infection) and also in some 
presently asymptomatic subjects (15 [11%] of the study population; one every three-final 
pericarditis, myopericarditis or myocarditis diagnosis). These long-term manifestations may be 
due to an inadequate innate and adaptative immune response. In recent months, important 
advances have been achieved in the understanding of the immunology of COVID-1910. 
However, there is still very limited data on the longer-term immunological consequences of past 
SARS-CoV-2 infection, and no study has specifically focused in the settings of pericarditis and 
myocarditis. Herein, in-depth investigation of the distribution of major and minor populations of 
immune cells in blood showed a high frequency of overall altered immune profiles. Several of 
the immune cell alterations identified mimic abnormalities reported during active infection, 
including decreased eosinophil, NK-cell, and (plasmacytoid) dendritic cell counts29,30. In 
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contrast, other alterations are described here for the first time and have not been reported during 
the acute phase of the infection. These new alterations include abnormally high numbers of 
monocytes (i.e. recently produced classical monocytes) and lymphocytes, such as T-cells, 
particularly CD4-CD8-/lo, TCD4 cells and TCD8 cells, and B-lymphocytes together with 
decreased counts of myeloid-derived suppressor cells, immature (CD16-CD62L-) neutrophils, 
both immunomodulatory FcεRI+CD62L+ and intermediate (i.e. CD14+CD16+) monocytes and 
circulating plasma cells.  Altogether, these findings may partially reflect (the normal and an 
altered) immune recovery after SARS-CoV-2 infection. Thus, while persistence of eosinopenia 
and expansion of CD4-CD8-/lo T-cells in blood were detected across all groups of participants 
suggesting it is part of the immune recovery after COVID-19; NK-cells were specifically 
decreased among participants with myopericarditis and myocarditis in association with 
(persistent) tissue damage. Nonetheless, the altered immune profiles in participants without 
pericardial and myocardial manifestations, could also be due to persistence of tissue damage and 
recovery in other organs affected by SARS-CoV-2, such as the lung, more than just reflecting 
normal immune recovery. Anyhow, more detailed analysis of the altered immune profiles 
among the different groups of participants showed that those with myopericarditis or 
myocarditis had closer to normal lymphocyte counts, but reduced numbers in blood of 
circulating eosinophils, plasmacytoid dendritic cells and particularly, NK-cells. Such unique 
profile mimics what has been described recently during the acute phase of SARS-CoV-2 
infection, suggesting an ongoing cytotoxic response with increased tissue migration or death by 
apoptosis of specific subsets of cytotoxic cells. In line with this hypothesis, we found here lower 
numbers of granzymeB+CD57- memory and effector TCD8-, Tγδ- and/or NK-cells among 
participants with myopericarditis or myocarditis. Of note, these participants with myocardial 
injury also showed particularly lower counts in blood of (recently produced) plasma cells, 
together with lower anti-SARS-CoV-2-IgG plasma levels. These findings suggest that a less 
pronounced (potentially insufficient) or a delayed humoral response may occur in these 
subjects, which may lead to decreased neutralization, opsonization and/or clearance of the virus 
locally at the peri-myocardium; local viral persistence would favour an increased tissue-homing 
(or early death) of eosinophils, immunomodulatory and intermediate monocytes, in addition to 
cytotoxic (effector) cells. Altogether, the above findings suggest that an inadequate (potentially 
delayed) immune response might happen in a substantial fraction of patients with past SARS-
CoV-2 infection, with differently altered profiles in subjects who present myopericarditis or 
myocarditis.  
Limitations of the study 
The study analysis was limited to health-care workers in Salamanca and therefore may 
have limited external generalizability to other non-health-care settings. However, the strength of 
this study is the addition of non-hospitalized participants and also the inclusion of participants 
diagnosed of past SARS-CoV-2 infection through serology, who also had a high prevalence of 
pericarditis and myocarditis. Seropositive participants, although less symptomatic than RT-PCR 
participants, presented mild symptoms in almost all cases; unfortunately, we cannot draw 
conclusions regarding the prevalence of pericarditis and myocarditis in the completely 
asymptomatic general population. Finally, the study relied solely on descriptive observations 
and cannot provide any conclusion on the benefit of antiviral and anti-inflammatory treatments 
during the acute phase of infection or whether the prevalence of pericarditis and myocarditis 
after SARS-CoV-2 infection is higher in women than men. 
Conclusions 
This study shows that pericarditis and myocarditis are frequent long after SARS-CoV-2 
infection and also in some presently asymptomatic subjects; in addition, we provide herein 
evidence for an altered immune cell distribution in blood which affects cells involved in both 
the innate (e.g. eosinophils and monocytes) and the adaptative cellular (e.g. CD4-CD8-/loTαβ+, 
TCD4 and TCD8 T-cells) and humoral (e.g. plasma cells and anti-Sars-CoV-2 IgG levels) 
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immune responses; nonetheless, a direct link between such altered immune profiles and the 
presence of pericardial and myocardial injury still needs to be established. These observations 
will probably apply to the general population infected, and may indicate that cardiac sequelae 
might occur late. Although all study participants presented clinical stability and non-severe 
cardiac complications, prospective monitoring will be necessary to address the future clinical 
consequences of these findings. 
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Figure 1: Flowchart for participant selection among health-care workers. All clinical 
suspicions of SARS-CoV-2 infection, RT-PCR and anti-SARS-CoV-2 antibodies test 
management, result information, and preventive and isolation actions for Salamanca´s health-
care workers have been managed through the Occupational Health Service from the University 
Hospital of Salamanca during the COVID-19 pandemic; making it easy to identify health-care 
workers candidates for the study. 
 
Figure 2: Pericarditis, myopericarditis and myocarditis criteria combinations. Description 
of pericarditis clinical criterions and updated Lake-Louise-Criteria for myocarditis in 
participants diagnosed with pericarditis, myopericarditis or myocarditis. CRP= C-reactive 
protein; ECG= electrocardiogram; ECV= increase of T1-extracellular volume; Effusion= 
pericardial effusion assessed at cardiac magnetic resonance; LGE= T1-late gadolinium 
enhancement; LV= systolic left ventricular wall motion abnormalities; T1map= increase of 
native myocardial T1-relaxation time; T2 map= increase of myocardial T2-relaxation time; 
T2W= increase of T2-weighted hyperintensity; Thickened= pericardial thickness greater or 
equal to 3 mm. 
 
Figure 3: Pericarditis and myocarditis prevalence by SARS-CoV-2 infection laboratory 
diagnosis. Prevalence of pericarditis or myocarditis, pericarditis, myopericarditis and 
myocarditis in participants with SARS-CoV-2 infection diagnosed through RT-PCR or through 
serology.  
 
Figure 4: Altered immune cell profiles and antibody serum levels in the health-care 
workers grouped according to the presence vs absence of pericarditis, myopericarditis and 
myocarditis. A: t-SNE graphical representation of the distribution of the major immune cell 
populations in blood of a healthy donor (T-SNE plot in the left) and a participant diagnosed 
with pericarditis (t-SNE middle plot) showing both increased Tab+CD4-CD8-/lo T cell and 
decreased eosinophil counts in blood. B: 2-dimension graphical representation of multivariate 
canonical (linear discriminant) analysis plots showing the presence of overall different immune 
cell profiles in blood of the participants with past SARS-CoV-2 infection (n=139; coloured 
circles) vs age-matched healthy donors (n=463; grey squares) (two plots in the left); distinct 
immune cell profiles were also observed between participants diagnosed with pericarditis (blue 
circles) and myocarditis (orange circles); most myopericarditis cases (red circles) shared an 
altered immune cell profile in blood similar to that of myocarditis. C: Frequency and amount of 
anti-SARS-CoV-2 antibodies measured in plasma of 123/139 participants grouped according to 





Table 1. Baseline characteristics of the study cohort 













Median (range) age (years) 52 (41–57) 52 (38–57) 45 (34–52) 54 (44–60) 52 (48–57) 0.503 
Female sex 100 (72) 56 (67) 3 (75) 12 (80) 29 (81) 0.400 
Health care worker category     0.669 
     Medical staff 35 (25) 22 (26) 1 (25) 6 (40) 6 (17)  
     Nurse 49 (35) 28 (33) 1 (25) 4 (27) 16 (44)  
     Other 55 (40) 34 (40) 2 (50) 5 (33) 14 (39)  
Direct attention to COVID-19 patients 67 (48) 40 (48) 3 (75) 7 (47) 17 (47) 0.814 
Coexisting conditions      
     Obesity
*
 17 (12) 14 (17) 1 (25) 0 2 (6) 0.108 
     Hypertension 17 (12) 11 (13) 1 (25) 1 (7) 4 (11) 0.679 
     Diabetes 2 (1) 2 (2) 0 0 0 1.000 
     Dyslipidaemia 27 (19) 17 (20) 1 (25) 2 (13) 7 (19) 0.936 
     Current smoking 6 (4) 4 (5) 0 1 (7) 1 (3) 0.741 
     Past smoking 70 (50) 43 (51) 0 6 (40) 21 (58) 0.140 
     Alcohol use
†
 23 (16) 10 (12) 1 (25) 3 (20) 9 (25) 0.217 
     Cardiovascular disease 8 (6) 5 (6) 0 2 (13) 1 (3) 0.472 
     Pulmonary disease
‡
 8 (6) 5 (6) 0 0 3 (8) 0.805 
     Sleep apnoea-hypopnea syndrome 8 (6) 5 (6) 0 2 (13) 1 (3) 0.472 
     Chronic kidney disease 5 (4) 2 (2) 0 0 3 (8) 0.319 
     Cancer 4 (3) 3 (4) 0 0 1 (3) 1.000 
     Al least of the above 106 (76) 64(76) 3 (75) 9 (60) 30 (83) 0.287 
Daily physical activity 86 (62) 47 (56) 3 (75) 11 (73) 25 (69) 0.376 
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SARS-CoV-2 infection diagnosis      0.274 
     RT-PCR 103 (74) 59 (70) 3 (75) 14 (93) 27 (75)  
     Anti-SARS-CoV-2-IgG antibodies 36 (26) 25 (30) 1 (25) 1 (7) 9 (25)  
Symptoms at SARS-CoV-2 infection      
     General      
          Fatigue 117 (84) 68 (81) 3 (75) 14 (93) 32 (89) 0.453 
          Fever 94 (68) 60 (71) 4 (100) 12 (80) 18 (50) 0.044
**
 
          Cough 91 (65) 57 (68) 3 (75) 10 (67) 21 (58) 0.768 
          Headache 90 (65) 52 (62) 2 (50) 11 (73) 25 (69) 0.697 
          Myalgia 83 (60) 46 (55) 4 (100) 9 (60) 24 (67) 0.255 
          Anosmia 73 (52) 41 (49) 3 (75) 9 (60) 20 (56) 0.643 
          Ageusia 66 (47) 34 (40) 3 (75) 7 (47) 22 (61) 0.133
**
 
          Abdominal pain or diarrhoea 64 (46) 37 (44) 1 (25) 7 (47) 19 (53) 0.722 
          Chills 60 (43) 34 (40) 2 (50) 7 (47) 17 (47) 0.861 
          Score throat 55 (40) 31 (37) 1 (25) 6 (40) 17 (47) 0.719 
          Nausea or vomiting 30 (22) 16 (19) 1 (25) 6 (40) 7 (19) 0.294 
          Clumsiness 20 (14) 13 (15) 0 3 (20) 4 (11) 0.801 
          Memory loss 19 (14) 12 (14) 0 2 (13) 5 (14) 1.000 
          Skin lesions 5 (4) 3 (4) 0 0 2 (6) 0.827 
     Cardiac       
          Shortness of breath 68 (49) 36 (43) 3 (75) 11 (73) 18 (50) 0.112
¶
 
          Palpitations 44 (32) 24 (29) 3 (75) 9 (60) 8 (22) 0.013
¶
 
          Chest pain 40 (29) 22 (26) 2 (50) 5 (33) 11 (31) 0.658 
          Dizziness 4 (3) 0 0 3 (20) 1 (3) 0.003
 ¶
 
          At least one cardiac symptom 86 (62) 46 (55) 3 (75) 13 (87) 24 (67) 0.085
 ¶
 
COVID-19 confirmed pneumonia 27 (19) 20 (24) 1 (25) 4 (27) 2 (6) 0.059
**
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Cardiovascular chronic drug therapy      
     ACE inhibitors or ARB 8 (6) 6 (7) 0 0 2 (6) 0.896 
     Beta-blocker 2 (1) 1 (1) 0 1 (7) 0 0.321 
     Statin 17 (12) 16 (19) 0 1 (7) 0 0.013
 **
 
     Antiplatelet 5 (4) 5 (6) 0 0 0 0.468 
     Anticoagulant 4 (3) 2 (2) 0 1 (7) 1 (3) 0.493 
Treatment at SARS-CoV-2 infection      
     Required hospitalization 23 (16) 19 (23) 1 (25) 2 (13) 1 (3) 0.025
 **
 
     Oxygen therapy 15 (11) 13 (15) 0 1 (7) 1 (3) 0.185
 
 
     Paracetamol 124 (89) 76 (90) 4 (100) 11 (73) 33 (92) 0.247 
     Ibuprofen 17 (12) 9 (11) 0 5 (33) 3 (8) 0.102
¶
 
     Azithromycin 57 (41) 36 (43) 2 (50) 7 (47) 12 (33) 0.709 
     Hydroxychloroquine 33 (24) 25 (30) 1 (25) 4 (27) 3 (8) 0.055
 **
 
     Lopinavir-ritonavir 17 (12) 14 (17) 1 (25) 1 (7) 1 (3) 0.083
**
 
     Oral glucocorticoids 9 (6) 4 (5) 1 (25) 2 (13) 2 (6) 0.171 
     High-dose intravenous glucocorticoids
§
 15 (11) 12 (14) 1 (25) 1 (7) 1 (3) 0.141 
     Interleukin-6 inhibitors (tocilizumab, siltuximab) 18 (13) 14 (17) 1 (25) 2 (13) 1 (3) 0.094
**
 
     Interleukin-1 inhibitor (anakinra) 2 (1) 2 (2) 0 0 0 1.000 
Additional drug therapy at examination       
     Inhaled glucocorticoids 5 (4) 3 (4) 0 0 2 (6) 0.862 
     Oral glucocorticoids 2 (1) 1 (1) 0 1 (7) 0 0.321 
     Low-molecular weight heparin 4 (3) 3 (4) 0 1 (7) 0 0.366 
Data are n (%) and median (range). *Obesity was considered if body-mass index of 30 or more. †Alcohol use was considered an average of at least one 
drink a day. ‡All participants with previous pulmonary disease referred asthma. §High-dose intravenous glucocorticoids was considered when at least a 
bolus of methylprednisolone of 250 mg was administered. P value for comparison among the four participants groups. Additional p value comparisons: 
 p value <0·05 no (non-pericardial and myocardial manifestations) vs presence of pericardial and myocardial manifestations; ¶p value <0·05 no (non-
pericardial and myocardial manifestations) vs myopericarditis; **p value <0·05 no (non-pericardial and myocardial manifestations) vs myocarditis. 
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      Table 2. Study measures at examination 













Time from symptoms onset to examination (weeks) 10.4 (9.3–11.0)
*
 10.4 (9.0–11.1) 9.0 (6.9–13.3) 10.4 (9.9–10.9) 10.3 (9.3–11.1) 0.841 
Time from SARS-CoV-2 test to examination (weeks)      
     RT-PCR 9.4 (8.1–10.0) 9.6 (7.9–10.1) 7.0 (5.7–8.6) 9.5 (9.1–10.4) 9.4 (8.6–10.0) 0.170 
     Anti-SARS-CoV-2-IgG antibodies
†
 4.4 (3.6–5.0) 4.6 (3.1–5.0) 4.3 2.3 4.0 (3.6–4.8) 0.501 
Vital signs at examination      
     Blood pressure (mm Hg)      
          Systolic 124 (113–139) 125 (115–142) 127 (114–142) 121 (112–139) 114 (107–136) 0.073
**§§
 
          Diastolic 76 (70–83) 77 (71–85) 77 (75–82) 77 (71–82) 72 (64–78) 0.062
**§§
 
     Heart rate (bpm) 70 (63–80) 70 (63–82) 68 (64–88) 70 (57–73) 72 (63–80) 0.816 
     Oxygen saturation <95%  10 (7) 9 (11) 1 (25) 0 0 0.043 
Physical examination      
     Pericardial rub 0 0 0 0 0 1.000 
     Heart murmur 3 (2) 3 (4) 0 0 0 0.713 
     Third and fourth heart sound 0 0 0 0 0 1.000 
     Pulmonary crackles 5 (4) 4 (5) 0 1 (7) 0 0.391 
Symptoms at examination      
     No symptoms 48 (34) 33 (39) 0 3 (20) 12 (33) 0.274 
     General      
          Fatigue 37 (27) 23 (27) 1 (25) 4 (27) 9 (25) 0.982 
          Anosmia 12 (9) 5 (6) 1 (25) 1 (7) 5 (14) 0.188 
          Ageusia 7 (5) 4 (5) 1 (25) 0 2 (6) 0.307 
          Headache 7 (5) 4 (5) 0 2 (13) 1 (3) 0.455 
          Sore throat 7 (5) 3 (4) 0 1 (7) 3 (8) 0.515 
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          Abdominal pain 6 (4) 3 (4) 0 1 (7) 2 (6) 0.625 
          Memory loss 4 (3) 2 (2) 0 0 2 (6) 0.770 
          Join pain 3 (2) 1 (1) 0 2 (13) 0 0.071 
          Piloerection 2 (1) 1 (1) 1 (25) 0 0 0.068 
     Cardiac       
          Dyspnoea or shortness of breath 36 (26) 20 (24) 2 (50) 7 (47) 7 (19) 0.115 
          Chest pain 27 (19) 8 (9) 3 (75) 11 (73) 5 (14) <0.001
**††‡‡
 
               Pericarditis like 18 (13) 3 (4) 3 (75) 11 (73) 1 (3) <0.001
**††‡‡
 
          Palpitations 20 (14) 10 (12) 2 (50) 3 (20) 5 (14) 0.163 
          Dizziness  8 (6) 2 (2) 1 (25) 2 (13) 3 (8) 0.040 
          At least one cardiac symptom 58 (42) 28 (33) 4 (100) 11 (73) 15 (42) 0.002
**††‡‡
 
Electrocardiographic measures      
     Sinusal rhythm 139 (100) 84 (100) 4 (100) 15 (100) 36 (100) 1.000 
          Sinus tachycardia over 100 beats per minute 2 (1) 1 (1) 0 0 1 (3) 0.637 
          Sinus bradycardia under 50 beats per minute 5 (4) 3 (4) 0 0 2 (6) 0.827 
     Extrasystole 2 (1) 2 (2) 0 0 0 1.000 
     AV block or bundle branch block 9 (6) 7 (8) 0 0 2 (6) 0.755 
     Intraventricular conduction delay 15 (11) 9 (11) 0 1 (7) 5 (14) 0.903 
     ST-segment depression or T-wave inversion 23 (16) 16 (19) 1 (25) 1 (7) 5 (14) 0.547 
     New Q waves 0 0 0 0 0 1.000 
     Long-QT interval
‡
 5 (4) 4 (5) 0 1 (7) 0 0.391 
     Low voltages 5 (4) 1 (1) 0 2 (13) 2 (6) 0.069 
     Early repolarization 8 (6) 7 (8) 0 0 1 (3) 0.576 
     Pericarditis like changes      
          Widespread ST elevation 13 (9) 7 (8) 0 5 (33) 1 (3) 0.017
‡‡
 
          PR depression 33 (24) 17 (20) 2 (50) 8 (53) 6 (17) 0.016
‡‡
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Laboratory measures      
     Glomerular filtration rate <60 ml/min x 1.73m
2
 2 (1) 0 1 (25) 0 1 (3) 0.033 
     High-sensitivity troponin T> 14 pg/ml
§
 1 (1) 0 0 0 1 (3) 0.396 
     NT-pro-BNP≥ 125 pg/ml  11 (8) 5 (6) 0 2 (13) 4 (11) 0.541 
     C-reactive protein >3 mg/dl 10 (7) 5 (6) 1 (25) 0 4 (11) 0.222 
CMR imaging measures      
     Increase of myocardial T2-relaxation time 6 (4) 1 (1) 0 1 (7) 4 (11) 0.066
**§§
 
     T2-weighted hyperintensity 6 (4) 0 0 1 (7) 5 (14) 0.006**§§ 
     Increase of native myocardial T1-relaxation time 58 (42) 24 (29) 0 7 (47) 27 (75) <0.001
**§§
 
     Increase of T1-extracellular volume 52 (37) 17 (20) 0 9 (60) 26 (72) <0.001
**‡‡§§
 
     T1-late gadolinium enhancement 10 (7) 2 (2) 0 4 (27) 4 (11) 0.008
**‡‡
 
     Pericardial effusion
 
 42 (30) 4 (5) 3 (75) 15 (100) 20 (57) <0.001
**‡‡§§
 
     Pericardial thickening
¶
 1 (1) 0 0 1 (7) 0 0.137 
     Systolic left ventricular wall motion abnormalities 7 (5) 3 (4) 0 0 4 (11) 0.340 
Data are n (%) and median (IQR). *Data regarding time from symptoms onset to examination was not possible to calculate for 2 patients who were totally 
asymptomatic. †Only one case with pericarditis and another case with myopericarditis in participants diagnosed of past SARS-CoV-2 infection through serology. 
‡Long-QT interval was defined as a rate-corrected (Bazett) QT interval exceeding 450 milliseconds in males and 460 milliseconds in females. §The 99th percentile of 
troponin values for our laboratory is 14 pg/ml.  Pericardial effusion greater than 3 mm. ¶Pericardial thickness of 3 mm on T1-weighted spin-echo CMR. P value for 
comparison among the four participants groups. Additional p value comparisons: **p value <0·05 no (non-pericardial and myocardial manifestations) vs presence of 
pericardial and myocardial manifestations; ††p value <0·05 no (non-pericardial and myocardial manifestations) vs pericarditis; ‡‡p value <0·05 no (non-pericardial 
and myocardial manifestations) vs myopericarditis; §§p value <0·05 no (non-pericardial and myocardial manifestations) vs myocarditis.  
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Neutrophils 3723 (2969–4613) 3430 (2633–4225) 0.004
*§
 3413 (2647–4122) 2767 (2386–5975) 3734 (3121–4249) 3290 (2318–4407) 0.650 




p  – 18 (13) / 5 (5) <0.001 / 0.001 9 (11) / 5 (6) 0 / 0  1 (7) / 0 8 (22) / 2 (6) 0.299 / 0.794 
     MDSC-like Neutrophils 5 (2–12) 2 (1–5) <0.001
*‡§
 3 (1–8) 2 (0.7–28) 2 (0.7–3) 2 (1–4) 0.270 




 5 (2–9) 2 (0.8–4) <0.001
‡§
 2 (0.9–6) 2 (0.6–23) 0.9 (0.6–2) 2 (0.8–3) 0.280 




 0.5 (0.2–1) 0.5 (0.3–1) 0.920 0.5 (0.3–1) 0.5 (0.2–5) 0.3 (0.1–0.9) 0.4 (0.2–0.8) 0.270 
Eosinophils 157 (101–249) 74 (47–149) <0.001
*†‡§
 82 (50–120) 34 (31–164) 61 (46–126) 105 (50–179) 0.340 




p – 38 (27) / 1 (0.7) <0.001 / 0.200 21 (25) / 1 (1) 3 (75) / 0 4 (27) / 0 10 (28) / 0 0.840 / 0.883 
Basophils 38 (21–52) 47 (35–62) 0.013
*d
 48 (37–52) 34 (13–55) 34 (29–56) 51 (38–64) 0.210 




p – 4 (2) / 5 (3) 0.001 / 0.001 1 (1) / 3 (3) 1 (25) / 1 (25) 1 (6) / 1 (6) 1 (2) / 0 0.842 / 0.672 
Monocytes 317 (245–433) 405 (328–523) <0.001
*
 421 (346–528) 376 (351–785) 385 (297–442) 368 (292–557) 0.330
 ¶
 




p – 7 (5) / 6 (4) <0.001/ <0.001 4 (5) / 3 (4) 0/ 1 (25) 3 (20) / 0 0 / 2 (6) 0.185 / 0.650 
     Classical monocytes 290 (240–383) 386 (308–492) <0.001
*
 423 (356–500) 382 (319–669) 376 (308–518) 341 (272–409) 0.059
 ¶
 




 46 (7–70) 12 (3–56) 0.038
‡§
 18 (5–73) 4 (1–15) 2 (0.7–6) 11 (3–34) 0.020
¶
 




 205 (132–269) 230 (156–304) 0.170
*
 245 (160–330) 263 (248–580) 189 (54–293) 196 (156–252) 0.057
¶
 




 7 (2–33) 2 (0.3–7) 0.001
*‡§
 2 (0.3–9) 0.4 (0.1–4) 0.5 (0.1–7) 2 (0.3–7) 0.740 




 101 (52-258) 39 (18–77) <0.001
*†§
 35 (16–77) 23 (13–36) 49 (19–100) 47 (28–72) 0.560 
     Intermediate monocytes 20 (15–29) 14 (9–20) 0.001
*‡§
 15 (10–21) 9 (4–14) 13 (5–17) 13 (9–18) 0.150 
     Non-classical monocytes 49 (36–62) 42 (27–63) 0.170 43 (27–63) 36 (13–51) 45 (11–73) 39 (27–58) 0.730 
Dendritic cells 29 (20–35) 28 (20–35) 0.620 29 (21–35) 28 (22–31) 29 (18–36) 23 (17–35) 0.420 




p – 14 (10) / 5 (3) <0.001 / 0.001 7 (8) / 5 (5) 1 (25) / 0 6 (40) / 0 0 / 0 0.556 / 0.343  
     Myeloid dendritic cells 18 (14–26) 19 (14–26) 0.600 19 (14–25) 20 (14–26) 21 (15–29) 17 (13–28) 0.800 
          CD1c
+
 m dendritic cells 17 (14–25) 19 (14–25) 0.570 19 (14–25) 19 (13–26) 20 (14–27) 16 (13–24) 0.790 
          CD141
+
 m dendritic cells 1 (0.6–1) 0.9 (0.6–1) 0.640 0.9 (0.6–1) 0.6 (0.5–0.7) 0.8 (0.7–1) 0.6 (0.5–1) 0.054 
     Plasmacytoid dendritic cells 8 (6–11) 6 (4–9) 0.020
§
 7 (5–10) 7 (2–12) 6 (4–8) 5 (4–8) 0.063 
     Axl
+
 dendritic cells 0.3 (0.2–0.4) 0.3 (0.2–0.5) 0.560 0.3 (0.2–0.5) 0.3 (0.2–0.4) 0.3 (0.2–0.5) 0.2 (0.1–0.3) 0.330 
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Data are median (IQR) of cells/μL of blood or n (%) of cases lower than 5th percentile (↓5thp) and higher than 95th percentile (↑95thp) for each cell subset in age-
matched healthy donors. Left p value for comparisons between healthy donors vs all participants. Right p value for comparison among the four participants groups. 
Additional p value comparisons: *p value <0·05 healthy donors vs no (non-pericardial and myocardial manifestations); †p value <0·05 healthy donors vs pericarditis; ‡p 
value <0·05 healthy donors vs myopericarditis; §p value <0·05 healthy donors vs myocarditis;  p value <0·05 no (non-pericardial and myocardial manifestations) vs 
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Lymphocytes 1675 (1332–2223) 2221(1717–2563) <0.001
*§
 2294 (1847–2779) 2392 (1729–3876) 1660 (1379–2070) 2105 (1717–2538) 0.006
¶††
 




p* – 3 (2) / 8 (6) 0.012 / <0.001 1 (1) / 6 (7) 0 / 1 (25) 2 (13) / 0 0 / 1 (3) 0.180 / 0.209 
     T cells 1246 (943–1642) 1652 (1348–1985) <0.001
*§
 1748 (1423–2003) 1831 (1280–2757) 1350 (1186–1480) 1664 (1350–2019) 0.011
¶**
 




p* – 1 (1) / 10 (7) 0.200 / <0.001 0 / 8 (10) 0 / 1 (25) 1 (7) / 0 0 / 1 (3) 0.379 / 0.187 
          CD4+ T cells 716 (567–961) 1017 (791–1213) <0.001
*§
 1036 (86–1271) 950 (846–1517) 841 (718–902) 1049 (729–1334) 0.049
¶††
 




p* – 1 (1) / 14 (10) 0.200 / <0.001 0 / 8 (10) 0 / 1 (25) 1 (7) / 0 0 / 5 (14) 0.379 / 0.175 
          CD8+ T cells 407 (291–590) 507 (388–696) <0.001
*§
 547 (399–762) 684 (323–1090) 403 (337–548) 523 (393–631) 0.089
¶
 




p* – 0 / 9 (6) – / <0.001 0 / 7 (8) 0 / 1 (25) 0 / 0 0 / 1 (3) – / 0.204 




Tαβ cells 46 (28–79) 78 (48–130) <0.001*†‡§ 90 (52–133) 137 (76–247) 71 (64–79) 67 (37–115) 0.056**§§ 




p* – 5 (4) / 24 (17) 0.003 / <0.001 4 (5) / 16 (19) 0 / 1 (25) 1 (7) / 2 (13) 0 / 5 (14) 0.526 / 0.845 
          Tγδ cells 56 (33–107) 59 (31–93) 0.580 59 (33–93) 113 (67–194) 49 (36–58) 46 (21–85) 0.077 ‡‡§§ 




p* – 2 (1) / 8 (6) 0.053 /<0.001 2 (2) / 6 (7) 0 / 1 (25) 0 / 0 6 (17) / 0 0.013 / 0.078 
     NK cells 260 (162-372) 213 (137–321) 0.007
‡§
 240 (143–337) 195 (142–341) 120 (82–289) 177 (137–256) 0.084
¶**
 




p* – 9 (6) / 6 (4) <0.001 / 0.001 4 (5) / 4 (5) 0 / 0 3 (20) / 0 2 (6) / 2 (6) 0.153 / 0.794 
     B cells 154 (108–228) 208 (158–297) <0.001
*†§
 233 (175–327) 303 (216–930) 167 (132–188) 202 (146–245) 0.011
¶**§§
 




p* – 2 (1) / 16 (12) 0.053 /<0.001 1 (1) / 10 (12) 0 / 1 (25) 1 () / 1 (7) 0 / 4 (11) 0.319 / 0.782 
     Plasma cells 2 (0.8–3) 0.8 (0.3–2) <0.001
*‡§
 0.8 (0.4–2) 1 (0.5–3) 0.4 (0.2–0.8) 1 (0.3–2) 0.140
¶
 




p* – 11 (8) / 1 (1) <0.001 / 0.200 6 (7) / 1 (1) 0 / 0 2 (13) / 0 3 (8) / 0 0.795 / 0.883 
Data are median (IQR) of cells/μL of blood or n (%) of cases lower than 5th percentile (↓5thp) and higher than 95th percentile (↑95thp) for each cell subset in age-
matched healthy donors. Left p value for comparisons between healthy donors vs all participants. Right p value for comparison among the four participants groups. 
Additional p value comparisons: *p value <0·05 healthy donors vs no (non-pericardial and myocardial manifestations); †p value <0·05 healthy donors vs pericarditis; ‡p 
value <0·05 healthy donors vs myopericarditis; §p value <0·05 healthy donors vs myocarditis;  p value <0·05 no (non-pericardial and myocardial manifestations) vs 
pericarditis. ¶p value <0·05 no (non-pericardial and myocardial manifestations) vs myopericarditis; **p value <0·05 no (non-pericardial and myocardial manifestations) 
vs myopericarditis plus myocarditis; ††p value <0·05 pericarditis vs myopericarditis; ‡‡p value <0·05 pericarditis vs myocarditis; §§p value <0·05 myopericarditis vs 
myocarditis. NK= natural killer.
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220 health care workers identified by the  Occupational Health Service of UHS in 
whom SARS-CoV-2 infection was confirmed with RT-PCR from 15 March to 25 
April 2020
229 health care workers identified by the  Occupational Health Service of UHS in 
whom SARS-CoV-2 infection was confirmed with anti-SARS-CoV-2-IgG 
antibodies from 10 April to 22 May 2020
106 signed the informed consent and examinations performed from 25 May to June 12
0 deaths
126 consecutively contacted to 
participate in the study




1 excluded from analysis as CMR was not completed for claustrophobia  
1 excluded from analysis as history of severe hypertrophic myocardiopathy
1 excluded for history of inherited immune deficiency
0 deaths
40 consecutively contacted to participate 
in the study
3 refused to participate 
1 gadobutrol allergy
189 never contacted
36 signed the informed consent and examinations performed from 25 May to June 12
139 clinical evaluation
laboratory with troponin, NT-pro-BNP, C-reactive protein, 
and cellular and humoral immune response assessments
electrocardiography
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